IL3 and chronic myelogenous leukemia, BCR-ABL1 positive: Bellavia et al. engineered HEK293T to express the EV protein Lamp2b, fused to a portion of interleukin 3 (IL3) to target specific cancer cells (chronic myelogenous leukemia); DiR was used to label the HEK293T-derived EVs (Bellavia et al., 2017).